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Background: Bacterial vaginosis (BV) is a common gynecologic diagnosis characterized by dysbiosis of the vaginal
microbiota. It is often accompanied by vaginal symptoms such as odor and discharge, but can be asymptomatic.
Despite over 50 years of research, the etiology of BV is not well understood, which is a major impediment to
treatment and prevention of BV.
Results: Here we report on the temporal dynamics of 25 vaginal communities over a 10 week period using
samples collected daily from women who were diagnosed with symptomatic BV (15 women), asymptomatic
BV (6 women), and women who did not have BV (4 women).
Conclusion: This unique resource of samples and data will contribute to a better understanding of the role that
the vaginal microbes have in the natural history of BV and lead to improved diagnosis and treatment.Background
Bacterial vaginosis (BV) is the most common vaginal
condition of women of reproductive age, resulting in
millions of healthcare visits annually in the United States
alone [1]. Women with BV typically report symptoms
that include a thin vaginal discharge and a fishy malodor
[2]; however, a substantial portion of affected women are
asymptomatic [3]. Although the etiology of BV is incom-
pletely understood, it is well-documented that BV is ac-
companied by, and perhaps caused by, disruption of the
vaginal ecosystem that is reflected in alterations to the
composition and structure of vaginal microbial com-
munities [4,5]. In women with BV, there are reduced
proportions of lactic acid–producing bacteria (primarily
Lactobacillus spp.) and increases in the number and
diversity of facultative and strictly anaerobic bacteria, in-
cluding species of Gardnerella, Prevotella and other taxa* Correspondence: jravel@som.umaryland.edu; lforney@uidaho.edu
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stated.of the order Clostridiales [4]. BV has been shown to be
an independent risk factor for adverse outcomes,
including preterm delivery and low infant birth weight,
the development of pelvic inflammatory disease [6] and
increased risk of acquiring sexually transmitted infec-
tions and HIV [7-10]. National surveys estimate that the
prevalence of BV among US women is 29% [11], and,
despite the high burden of this disease, the events that
precipitate BV remain obscure. BV is particularly troub-
ling for patients and clinicians, as recurrence of BV follo-
wing antibiotic treatment is common [12] and the arsenal
of treatment includes just two antibiotics, namely, topical
or oral metronidazole and clindamycin [2].
In clinical settings, BV is often diagnosed based on the
criteria described by Amsel et al. [13], wherein three of
the following four signs must be evident: (1) a homoge-
neous, white, noninflammatory discharge that smoothly
coats the vaginal walls; (2) the presence of clue cells (squa-
mous epithelial cells covered with adherent bacteria) upon
microscopic examination; (3) a vaginal fluid pH over 4.5;
and (4) a fishy odor after addition of 10% KOH to vaginal
secretion samples. In research and laboratory settings, BVtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ginal smear [14-16]. One scoring method described by
Nugent et al. [14] reflects the relative abundance of
large Gram-positive rods (lactobacilli), Gram-negative and
Gram-variable rods and cocci (including, G. vaginalis,
Prevotella, Porphyromonas and peptostreptococci) and
curved Gram-negative rods (Mobiluncus). The relative
proportions of these different bacterial morphotypes give
rise to a score that ranges from 0 to 10. A score of 0 to 3
is considered healthy, 4 to 6 is intermediate and 7 to 10 is
indicative of BV. A weakness of diagnostic tests based on
Gram-stained smears is the subjective nature of assessing
bacterial cell morphology [17]. Gram staining can be
performed on self-collected vaginal smears [18], which
is critical for the success of longitudinal, field-based
studies [19,20].
Previous studies of BV have focused largely on women
who presented to their physicians with symptoms or co-
horts of women who were treated for BV and followed for
extended observational periods with infrequent sampling.
In one such study, Srinivasan et al. followed women diag-
nosed with BV daily for 7 days, then at 2, 3 and 4 weeks,
and used quantitative PCR to determine the abundance of
specific populations in vaginal samples [21]. The study
demonstrated that vaginal microbiota are dynamic and
that antibiotic treatment for BV rapidly reduces the num-
ber of facultative and strictly anaerobic species, but these
bacteria later reemerged. These findings are consistent
with the well-known phenomena of recurrent BV, in
which the signs and symptoms of BV are alleviated by
antibiotic use but return in the days and weeks that follow
a course of therapy. These patterns of recurrence suggest
that the vaginal environments of these women select for
various populations of anaerobes. A better understanding
of the events and conditions that cause shifts in the com-
position of the vaginal microbiome is needed to devise
therapies that reduce the incidence of BV and its recur-
rence following antibiotic therapy.
In this study, we sought to evaluate the spectrum of
events that occur in vaginal microbial communities prior
to, during and after episodes of BV by characterizing the
composition and dynamics of vaginal bacterial com-
munities using high-throughput 454 pyrosequencing of
barcoded V1 to V3 regions of 16S rRNA genes. To do
this, we conducted a high-resolution prospective study in
which samples were collected daily from 135 women of
reproductive age over two menstrual cycles. Behaviors and
events that took place before, during and after BV epi-
sodes were recorded. Herein we report our initial findings
on the daily composition and relative abundance of bac-
teria in vaginal samples from 25 women, 15 of whom
experienced symptomatic BV (SBV), 6 who were diag-
nosed with asymptomatic BV (ABV) and 4 who remained
healthy during the 10-week study. These women wereselected on the basis of their clinical examinations and the
longitudinal patterns of changes in Nugent scores.
Methods
Participants and sample collection
Between September 2009 and July 2010, 135 nonpregnant
women of reproductive age were enrolled in a longitudinal
study at the University of Alabama at Birmingham. The
clinical study protocol was approved by the Institutional
Review Board of the University of Alabama at Birmingham
and the University of Maryland School of Medicine. Writ-
ten informed consent was appropriately obtained from all
participants.
At study entry, participants were asked to answer a
lengthy questionnaire on demographics as well as medical,
dental, obstetric, hygiene, sexual and behavioral histories.
They were also asked to self-collect three midvaginal
swabs daily for ten weeks. The first Copan ESwab (Copan
Diagnostics, Murrieta, CA, USA) was placed in RNAlater
(Ambion, Austin, TX, USA) for use in future metatran-
scriptomics analyses. A second Copan ESwab was placed
in Amies liquid transport medium for use later in ex-
tracting genomic DNA. Third, a Starplex double-headed
Dacron swab (Starplex Scientific, Cleveland, TN, USA)
was stored dry in a tube for later use in metabolomic and
metaproteomic analyses. One of the Dacron swabs was
also used to prepare a smear that was later Gram-stained
for Nugent scoring. In addition, the participants mea-
sured their vaginal pH using the CarePlan VpH test
glove (Inverness Medical Innovations, Waltham, MA,
USA). Finally, participants completed a diary each day
to record hygienic practices and sexual activities using a
standardized form on which all responses were pre-
coded. Pelvic examinations were performed at the time
of enrollment and at weeks 5 and 10 or at interim times
if the participant reported vaginal symptoms. A diagno-
sis of SBV was made when three of four Amsel criteria
were recorded by the clinician and the participants re-
ported symptoms spontaneously or upon direct ques-
tioning. ABV was defined as a finding of three of four
Amsel criteria, but without self-report of any vaginal
symptoms. Women diagnosed with SBV were treated
for BV using standard of care practices [22]. Women
with ABV were not treated. Clinical and selected daily
behavioral data are described in Additional file 1.
DNA extraction and purification
Genomic DNA was extracted from vaginal swabs that had
been stored in Amies liquid transport medium at −80°C.
We used a validated procedure [23-25] that includes steps
for enzymatic and physical lysis of bacterial cells followed
by purification of genomic DNA using a QIAsymphony ro-
botic platform and QIAGEN CellFree 500 kits (QIAGEN,
Valencia, CA, USA) according to the manufacturer’s
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high-quality genomic DNA from 300 μl of each sample re-
suspended from a vaginal swab (Additional file 2).
Polymerase chain reaction amplification and sequencing
of the V1 to V3 region of bacterial 16S rRNA genes.
The composition and abundance in vaginal bacterial
communities was determined using culture-independent
methods. The V1 to V3 hypervariable region of 16S rRNA
genes was amplified using an optimized barcoded primer
set targeting 27f [26] and 533r. Amplifications were per-
formed in 96-well plates using the HotStar HiFidelity
DNA Polymerase Kit (QIAGEN). Amplicons were quanti-
fied using the Quant-iT PicoGreen kit (Molecular Probes/
Invitrogen, Eugene, OR, USA), then equimolar amounts
(100 ng) of amplicons were mixed in a single tube prior
to purification with the Agencourt AMPure XP PCR
Purification System (Beckman Coulter, Brea, CA, USA).
Purified amplicon mixtures were sequenced by 454 pyro-
sequencing (454 Life Sciences, Branford, CT, USA) at the
Genomics Resource Center of the Institute for Genome
Sciences, University of Maryland School of Medicine.
Quality assurance
Sequence reads quality control, analysis and taxonomic
assignments
Individual reads were quality-checked to eliminate short or
chimeric reads, reads with ambiguous base pairs and those
with low-quality regions using the criteria described in the
Supplementary methods section. Taxonomic assignments
were performed using a combination of a phylogenetics-
based classifier and speciateIT software (www.speciateIT.
sourceforge.net) (Additional file 3).
Initial findings
A total of 1,657 samples (a mean of 66.3 per woman, and
a median of 67 per woman) were successfully sequenced,
and 8,757,681 high-quality sequenced reads were gene-
rated with a mean of 5,285 and median of 5,093 reads per
sample. Lower read counts were obtained for samples
from subject 3 and subject 5 (weeks 1 to 3); however, these
samples are still comparable to those with higher read
counts as demonstrated previously [27] and are included
in this data set. The mean read length was 485 bp (median
of 515 bp).
Unexpectedly, the vaginal microbiota prior to SBV
mainly comprised strict anaerobes, such as Atopobium,
Prevotella, Megasphaera, BV-associated bacterium 2 and
the facultative anaerobe G. vaginalis, and the vaginal pH
was elevated (>4.5) (Figure 1). During the 2- to 9-week
interval prior to the diagnosis of SBV, a few symptoms were
reported in daily diaries, but none of these prompted par-
ticipants to immediately seek medical attention. Women
who were diagnosed with ABV harbored vaginal micro-
biota that lacked significant proportions of Lactobacillusspp. and had symptoms similar to those of patients who
ultimately were diagnosed with SBV (Figure 1A and B).
Of note, Lactobacillus iners was consistently present in
women who had SBV or ABV, albeit in low proportions
(Figure 1 and Additional file 4: Figure S1). In most
women, the treatment of SBV reduced the proportion of
facultative and strict anaerobes and increased the rela-
tive proportions of Lactobacillus spp. (mainly L. iners)
(Figure 1D to F). This effect was short-lived, however,
and, in most individuals, the community returned to its
pretreatment state within 2 to 4 weeks. Community dy-
namics in women who had ABV or SBV appeared to be
highly personalized, with some women experiencing
rapid shifts in community composition (Figure 1A, F
and G) and others harboring stable, but Lactobacillus
spp.-depleted, microbiota (Figure 1B to E and H). The
vaginal microbiota of women who did not have SBV or
ABV were consistently dominated by Lactobacillus spp.
or Bifidobacterium, but were not always stable in terms
of the dominant species of Lactobacillus present.Future directions
We will use these data to examine shifts in vaginal mi-
crobial community composition in conjunction with epi-
demiological and behavioral data to better define BV and
identify patterns that predict an increased risk for the
disease. This study will be done using model-based sta-
tistical clustering and classification approaches to asso-
ciate microbial community composition and dynamics
with metadata and clinical diagnoses of health or BV.
The large body of information generated will facilitate
understanding vaginal microbial community dynamics
and the etiology of BV, and it will drive the development
of better diagnostic tools for use in the differential diag-
nosis of BV. Furthermore, we anticipate that the infor-
mation will enable a more personalized, more effective
treatment of BV and ultimately help to prevent adverse
sequelae associated with this highly prevalent disruption
of the vaginal microbiome.Supporting data
All sequence data and metadata were deposited in the Se-
quence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/
Traces/sra/) under BioProject PRJNA208535 (“The daily
dynamics of the vaginal microbiota before and after bac-
terial vaginosis”; http://www.ncbi.nlm.nih.gov/bioproject/?
term=PRJNA208535) ([SRP026107] and [SRA091234]).
Quantitative Insights Into Microbial Ecology (QIIME soft-
ware) mapping files are provided in Additional file 5.
Because of the sensitivity of the metadata and Insti-
tutional Review Board restrictions, additional meta-
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Figure 1 Daily temporal dynamics of vaginal bacterial communities. (A) and (B) Women diagnosed with asymptomatic bacterial vaginosis
(ABV) at some point during the ten-week period are shown. (C) to (H) women diagnosed with symptomatic bacterial vaginosis (SBV) at some
point during the ten-week period are shown. (A) through (H) Color codes for each phylotype represented in the interpolated bar plots are shown
next to each panel. Pink open circles indicate symptomology. Red closed circles indicate menstruation days. Large black open circles represent
ABV diagnosis. Large black closed circles represent symptomatic BV diagnosis. Small closed circles indicate BV medications used. Daily Nugent
scores (range: 0 to 10) and pH (range: 4 to 7) are indicated below the graphs. See Additional file 4: Figure S1 for interpolated bar plots for
all subjects.
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Additional file 1: Clinical and daily behavioral data.
Additional file 2: Supplementary methods.
Additional file 3: Relative proportions of taxa observed in all
samples.
Additional file 4: Figure S1. Daily temporal dynamics of vaginal
bacterial communities in 15 women who experienced symptomatic BV
diagnosis (A to O), asymptomatic BV only (P to U) at some point during
a 10-week period or no BV (V to Y). Color codes for each phylotype
represented in the interpolated bar plots are shown next to each panel.
Pink open circles: symptomology; red closed circles: menstruation days
(small circles indicate low bleeding, medium circles, medium bleeding
and large circles heavy bleeding); large black open circles: asymptomatic
BV diagnosis; large black closed circles: symptomatic BV diagnosis; small
closed circles: BV medication used. Daily Nugent scores (range 0–10)
and pH (range 4–7) are indicated below the graph.
Additional file 5: QIIME mapping files for each 454 sequencing run.
Abbreviation
PCR: Polymerase chain reaction.
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